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 INTRODUCTION 
Over the past 3 decades, platelet rich plasma has gained increased importance in 
various medical fields, including orthopedics. Several studies have shown the use 
the use of platelet rich plasma in management of soft tissue and bony injuries.  
Recently, platelet plasma has been used for cartilage regeneration, chronic 
enthasopathies like tennis elbow, plantar fasciitis, and in the field of sports 
medicine.  
  Very limited studies are available showing the effect of platelet rich plasma in 
human tissues. Platelet rich plasma was developed in early 1970s as a part of 
blood in which platelets are concentrated in plasma. The basic science of platelet 
rich plasma mainly depends on the growth factors in the alpha-granules. PDGF, 
TGF-BETA 1, EGF, and VEGF are the growth factors seen in platelet granules. 
These growth factors have effect on the healing process of many tissues. PGDF is 
platelet derived growth factor. It is found in alpha granules of platelets. PGDF has 
mytogenic potential for both mesenchymal and osteoblast cells. PGF is epidermal 
growth factor which also has mitogenic activity and it will stimulate and regulate 
collagen synthesis. FGF-fibroblast growth factor, TGF-beta- transforming growth 
factor beta, IGF-insulin like growth factor, VEGF- vascular endothelial growth 
factor and CTGF-connective tissue growth factor have similar potential activities 
depending upon which tissue they were acting. It is these growth factors which 
platelet rich plasma a potential substance for regeneration and differentiation of 
tissues and its use in treatment of various conditions.  
The majority of orthopedic applications of platelet rich plasma will fall into 4 
categories- 
1. Chronic tendenopathies 
2. Acute ligamentous injuries 
3. Muscle injuries 
4. Augmentation of other treatment modalities like bone grafting 
The treatment and complete cure from chronic enthasopathies like tennis 
elbow, plantar fasciitis, has always been ranked among the most difficult and 
frustrating problem for both patients and treating doctors. Tennis elbow or 
lateral epicondylitis has been described as a degenerative tendonopathy of 
extensor carpi radialis brevis muscle. The most common pathogenesis is 
repetitive micro trauma of muscle from overuse resulting in tendinosis of ECRB 
with or without involvement of extensor digitorum communis muscle. Various 
forms of conservative treatments are available for tennis elbow and the 
outcome of these treatments varies in patient to patient. Plantar fasciitis is 
also known as heel tennis, because the plantar fascia is constantly stretched at 
the attachment over  calcaneal tuberosity. Repeated micro trauma makes this 
disease difficult for conservative treatment. Surgical options like plantar fascia 
release were practiced but devastating complications will occur since plantar 
fascia is a supporting structure for maintain the longitudinal arch of the foot.  
 Platelet rich plasma had a biological healing capacity. Platelet rich plasma 
helps in healing both tennis elbow and plantar fasciitis and recurrence rate will 
be low. In this study we used intralesional injection of autologous platelet rich 
plasma for the treatment of chronic tennis elbow and plantar fasciitis. 
 
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES  
1. To study the efficacy of autologous platelet rich plasma in plantar fasciitis 
and tennis elbow. 
2. To compare the outcome of autologous platelet rich plasma injections 
between plantar fasciitis and tennis elbow patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
PLANTAR FASCIITIS: 
Enab Mohamed Selem Ragab et al in his literature on PRP for plantar fasciitis 
written that plantar fascia function as a supportive structure for longitudinal arch 
of the foot and it is a thick fibrous structure which originate from calcaneal 
tuberosity and the run forward towards the metatarsals (1). He also commented 
that plantar fascia will provide static support along with a dynamic shock 
absorption function (1). 
                    There are number of causes for heel pain out of which Plantar fasciitis 
is considered as common in adults (1). Collagen degeneration takes place at the 
origin of plantar fascia and this is the reason for pain in the heel (1). Plantar 
fasciitis can be diagnosed based on the history which was more in the morning 
and by the tenderness on palpation over medial calcaneal tubercle (2). The classic 
sign is the worst pain that occurs with the few steps in the morning or at the 
starting of the activity that decreases as they warm up (2).  
       Plantar fasciitis is considered as a degenerative pathology rather than an 
inflammatory process. This was supported by histological evidence where 
degeneration of plantar fascia along with cells representing chronic inflammation, 
with multiplication of fibroblasts was noted. The above findings were seen in 
operative specimens and were reported in Ertgrul Aksahin et al literature on PRP 
(2). 
   plantar fasciitis is a self limiting disease which will usually resolve in six to 
eighteen months (1). This long duration of symptoms will be a frustration for both 
patients and treating doctors (1). A conservative treatment is preferred in the 
initial period (2).  conservative treatment modalities include changes in daily 
activities, orthoses, stretching, taping, use of NSAID, extracorporeal shock wave 
therapy, focused shock wave therapy etc (1, 2, 4).local injections are used 
secondary for the treatment of resistant plantar fasciitis (2). Enab Mohamed 
Selem Ragab et al in their literature commented about local steroid injection and 
said that even though local steroid injection is a popular treatment method for 
plantar fasciitis , it was found that the actions will be short limited and high 
recurrence rate has been found (1). From early 1990s, ESWT has been used for 
treating chronic plantar fasciitis. Results ranged from 48 to 77% (1). 
The use of platelet rich plasma in regeneration of tissue is a developing area for 
clinicians and researchers and has been employed in various fields of surgery 
including orthopedics (5).  
TENNIS ELBOW: 
Tennis elbow or lateral epicondylitis is a common problem in office orthopedics 
and is reported to be 4 times as common in 4
th
 decade of life (7). The term 
‘epicondylitis’ suggests inflammation, although histological analysis found that 
tissue invariably fails to show inflammation (6). As its term implies, lateral 
epicondylytis had a high association with tennis, particularly on one handed back 
strokes.  40% to 50% of tennis players will suffer from this condition during their 
lifetime (11). Work which uses repeated pronation and supination movements, 
decreased carrying angle, sudden vigorous supination, weight lifting in extended 
and supinated forearm are the common predisposing factors (8). Rheumatoid 
arthritis, arthritic diasthysis, gout and focal sepsis etc suggested in determining 
the chronicity of the lesion (8).  
    Pathology of tennis elbow still remains unclear (9).  Most popular theory is that 
the conditions results from repeated contraction of the wrist extensor muscles, 
mainly the extensor Carpi radialis brevis causes microscopic tears that progress to 
the degenerative condition of tendinosis (9). Robert .E. Bunata et al, in their study 
of anatomic factors for the cause of tennis elbow concluded that the extensor 
Carpi radialis brevis tendon has a unique  location that makes its undersurface 
vulnerable during elbow motion  by contact and abrasion against the lateral edge 
of the capitellum  (9). Knaushaar and Nirschi evaluated surgical specimens 
collected with failed conservative treatment for tennis elbow using histology and 
electron microscopy found no evidence to suggest inflammatory process (9). 4 
stages of lateral epicondylitis have been described beginning with early 
inflammatory reaction, followed by angiofibroblastic degeneration, structural 
failure and ultimately fibrosis or calcification.  
      Tennis elbow affects approximately 1%-3% of the population (10). The 
condition is commonly seen in individuals between ages of 35 and 50 years. The 
dominant arm is most frequently affected (10).   
       Tennis elbow patients frequently describe pain or burning over the lateral 
humeral epicondyle that is increased by activities that require resistance to wrist 
extension (11). Tenderness at the lateral epicondyle and along the common 
extensor tendon and decreased grip strength is the common palpation findings in 
tennis elbow (11). Any test that generates pain by resisted wrist extension is an 
effective diagnostic tool (11). 
     Conservative treatment is the initial option for tennis elbow. Typical 
conservative treatment is rest, non- steroidal anti-inflammatory drugs (NSAIDs), 
braces, and physical therapy (10, 11, 12, and 13). Corticosteroid injection is 
considered once the above treatments fail but the effectiveness is now called in 
question (13). Extracorporeal shock wave, iontophoresis and botolin toxin 
injection are newer treatment options for tennis elbow (6, 13).  
    “ Platelet rich plasma is a bioactive component of whole blood, which is now 
being widely tested in different fields of medicine for its possibilities in aiding the 
regeneration of tissue with poor healing potential” (12). Several studies using 
platelet rich plasma to promote tendon healing are going worldwide (12). Mishra 
et al described Positive results of platelet rich plasma injection in patients with 
tennis elbow (33). Christos Thanasas et al, in their study on platelet rich plasma 
versus autologous whole blood for chronic tennis elbow supports use of PRP in 
treating tennis elbow patients (14).  
 
 
  
 
 
 
PLATELET RICH PLASMA 
 Portion of the plasma fraction of autologous blood having a platelet value above 
baseline is the definition of platelet rich plasma.  PRP not only contains more 
platelets but also the full complement of clotting factors and secretory proteins 
(15).  
   Platelets are formed in bone marrow and are the end products of 
megakaryocytes.  No nucleus is present in platelets and cannot replicate. Platelet 
lifespan is 5-9 days. Platelet plug is formed after tissue injury or surgery where 
platelets are exposed to damage blood vessels, which makes them direct contact 
with various extra-cellular proteins (15). Normal platelet counts is between 
150000/µL and 350000/µL, and average about 200000/µL in blood (16). “Platelet 
rich plasma was first promoted by M.ferrari in 1987 as an autologous component 
after an open heart operation to avoid homologous blood product transfusion” 
(18).since then PRP has been safely used in many fields including orthopedics 
(20). 
        Platelet is essential for tissue healing (19).  Clot formation and platelet 
activation is the first step in tissue healing (19). The platelet actions in tissue 
healing are by release of various growth and differentiation factors (19). “These 
factors are bioactive proteins responsible for attracting macrophages, 
mesenchymal stem cells, and osteoblasts which not only promotes removal of 
necrotic tissue, but also enhances tissue regeneration and healing”(20). 
          The main growth factors contained in alpha granules of platelets are 
transforming growth factor beta (TGF-beta), vascular endothelial growth factor 
(VEGF), platelet derived growth factor (PDGF), and endothelial growth factor 
(EGF)(14). Other growth factors are basic fibroblast growth factor, epidermal 
growth factor and connective tissue growth factors (19). 
       TGF-β sources are Platelets, extracellular matrix of bone, cartilage matrix, 
activated TH1 cells and natural killer cells, macrophages or monocytes and 
neutrophils. TGF-beta will 1, Stimulates undifferentiated mesenchymal cell 
proliferation. 2, regulates endothelial, fibroblastic, and osteoblastic mitogenesis. 
3, regulates collagen synthesis and collagenase secretion. 4-regulates mitogenic 
effects of other growth factors.5-stimulates endothelial chemo taxis and 
angiogenesis.6-inhibits macrophage and lymphocyte proliferation (19) 
                Platelet-derived growth factor sources are Platelets, osteoblasts, 
endothelial cells, macrophages, monocytes, and smooth muscle cells. The actions 
of PDGF are  
-Mitogenetic for mesenchymal cells and osteoblasts 
 -stimulates chemo taxis and mitogenesis in fibroblast, glial, or smooth muscle 
cells 
-regulates collagenase secretion and collagen synthesis 
- stimulates macrophage and neutrophil chemo taxis (19). 
 
              Vascular endothelial growth factor are growth factors derived from 
Platelets and from endothelial cells. The actions are  
-Increases angiogenesis and vessel permeability 
-stimulates mitogenesis for endothelial cells (19) 
           Connective tissue growth factor sources are Platelets through endocytosis 
from extracellular environment in bone marrow. Actions are 
- Promotes angiogenesis 
-promotes cartilage regeneration 
Promotes fibrosis and platelet adhesion (19) 
 
 
EFFECTS OF PRP IN DIFFERENT TISSUES 
    MUSCLE:  
    Kenneth S Lee in his article stated about cugat et al research on acute muscle 
injuries with PRP. The assessment was done clinically and ultrasonographicaly on 
the injured muscle. 50 percent of his patients had good clinical and functional out 
come(19). N Lindsay Harris in a study on rabbit tissues stated about the 
microscopic changes in normal muscle tissue following PRP injections.(37). He 
done studies on 18 rabbits. He injected ½ cc of PRP in to the tissues. 
           After two-weeks of platelet rich plasma injection he found features 
suggesting of inflammation. He  found inflammatory cells in the tissue. Calcium 
deposition was seen.  
        After six weeks of injection he noted the persistence of inflammation. The 
cells suggesting inflammation was seen. Necrosis of muscle with fibrosis and ca2+ 
also seen. Ca2+ deposited was found reabsorbed later. 
After 12 weeks of injection he did not notice any features suggesting of 
inflammation. 
 
Picture 1A 
 
 
Picture 1B 
 
 
 
 
  
 Picture 1C 
Picture A and B was muscle at 2 weeks and picture C was at 6 weeks. Features 
of inflammation can be seen in figure A and B, and calcium deposition at figure C 
which was noted by arrow marks. 
 
 
   
 
 
SUBCUTANEUS TISSUE: 
 
N Lindsay Harris in the above stated study also reported about the effect of PRP 
on subcutaneous tissues. At two weeks demonstrated Collagen nodules and 
fibrous tissue was noticed. Fibrous tissue and cells of inflammation replaces the 
subcutaneous fat.  
 At six weeks, Micro calcification was noted with cells of chronic inflammation 
near to it. 
At 12 weeks small calcification which was present previously and inflammatory 
cells was not seen 
 
 Picture2 A 
 
 
 Picture 2 B 
 
 
Picture 2A and 2B was at 12 weeks which shows collagen nodules and collagen 
fibers. 
 
 
 
 
 
 
 
 
 
TENDON: 
 
Samir Mehta in his article stated about the use of PRP in tendon injuries and 
tendinitis (15). Steven Sampson also in his article mentioned about the use of 
PRP in tendinopathies (20). There are many articles and studies supporting PRP 
use in tendon injuries.    N Lindsay Harris also stated about effect of PRP on 
rabbit tendon (37). At 2 weeks thick peritenon and cells of inflammation were 
noted. Vacuoles and inflammatory cells also seen in tendon tissue. Collagen 
bundles also seen.        
At six weeks, peritenon shows inflammation. 
At twelve weeks, inflammation decreased. 
Picture 3A 
 
Picture 3A shows no calcification at 2 weeks 
 
 
 
 
 
 
Picture 3B shows collagen formation at 2 weeks  
 
  
 
 
 
 
picture 3b 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIGAMENTS: 
 
 
Kenneth S Lee in his review literature mentioned about the studies of foster et al 
and Frie et al on acute ligament injuries (19). They found patients had 
accelerated return to their daily activities and sports. Pointing the above studies 
he stated that PRP will fasten the ligament healing and reduce the instability 
caused by ligament injuries (19). N Lindsay Harris in his study on normal rabbit 
tissue found that at two weeks, the tissues were thick which showed 
inflammation and 6 and 12 weeks showed very minimal inflammation after PRP 
injection (37). 
 
WOUND HEALING: 
 
Wound healing can be accelerated by the application of platelet rich 
plasma. The following diagram (diag: 1) explains about the phases of 
wound healing and the time of platelets action. In PRP platelets are in high 
concentration which will release the growth factors responsible for wound 
healing.  Various studies had been conducted in animal models and human 
trials explaining the effect of PRP on wound healing. Samir Mehta in his 
literature on platelet rich concentrate mentioned about the studies 
conducted by D R Knighton et al and C Gaino et al (15). 17 out 21 patients 
had re epithelialization and 78 percent of patients had limb salvage in D R 
Knighton et al and C Gaino et al studies respectively. PRP was also used 
in the donor site for split skin graft. PRP will fasten the epithelialization and 
reduce the crusting interval (15). Steven Sampson in his literature on the 
effect of PRP on musculoskeletal injuries stated about the studies of 
Crovetti et al and McAleer et al (20). Nine out of twenty four and twenty out 
of twenty four had complete healing of chronic ulcers in Crovetti et al and 
McAleer et al studies respectively. 
 
 
 
 
Diagram: 1   
BONE: 
 
The effect of platelet rich plasma on bone healing is a topic of debate. Even 
though some animal studies were not supporting PRP use, most of the 
studies had positive results (15). Growth factors like PDGF and TGF-β 
promote bone healing when used in conjunction with bone grafts. J 
Alsousou et al in their article on application of platelet rich plasma in 
orthopedics stated about the study of Bielecki et al and found that 13 out of 
20 non unions complete union was obtained after PRP application(5). In 
the same article a study on analyzing the levels of growth factors in fracture 
hematoma found that no growth factors in non union. In the same article a 
study of Kitoh et al on distraction osteogenesis was described and found 
callus formation at 34 to 47 days. Alsousou also commented about use of 
PRP in diabetic fractures. It was found that growth factors low in diabetic 
fracture callus. PRP once infiltrated to diabetic fractures will fasten the 
healing process (5). Samir Mehta in his article on platelet rich concentrate 
commented about the use of PRP in nonunion (15). He stated that PRP 
can promote bone healing if adequate bone approximation was present 
and not in gap nonunion.  
 
   
JOINT: 
 
N Lindsay Harris in his study on rabbit injected PRP in to normal tarsal joint 
with a control of normal saline injection. He found features suggestive of 
synovitis in all with nodules (picture 4a shows normal saline specimen and 
picture 4b with PRP) in one specimen at two weeks and histological 
response similar to calcification in subcutaneous tissue at 4 weeks. At six 
and twelve weeks all the specimens shows normal findings as in normal 
saline specimen (37). 
 
 
 
Picture 4a and 4b 
 
 
SAFETY OF PLATELET RICH PLASMA 
 
      Samir Mehta in his article on platelet rich concentrate mentioned about 
the safety of autologous concentrate (15). He stated that since it is 
prepared from the patient’s own blood the risk of transmission of 
communicable disease is nil. He also mentioned about the contra 
indications of PRP in patients with coagulation diseases and 
hypersensitivity to the products like bovine thrombin. 
 
Ertugrul aksahin in his study on plantar fasciitis with PRP and steroids 
concluded that PRP was equally effective as steroid injection and is 
superior because the complications like fat necrosis can be avoided (2). 
 
Joost C Peerbooms et al in a study on tennis elbow with PRP found no 
local and systemic complications except for increase of pain during the 
initial days following PRP injection because of inflammatory process (10). 
 
Bielecki et al in a study to find the antibacterial effect of autologous PRP 
against methicillin sensitive staph aureus and supports the growth of 
pseudomonas aeruginosa (38). 
 
 
 
 
PLATELET RICH PLASMA PREPARATION 
 
                   Different studies used various methods for preparing PRP. Keith S 
Hetchman et al prepared PRP by a commercially available kit known as cascade 
autologous platelet system. They collected 9 ml of patient’s blood in to a tube 
containing 1 ml of trisodium citrate and thioxotropic separation gel. The blood 
collected tube was centrifuged for 6 minutes at 1100g (relative centrifugal force). 
After initial centrifugation plasma is separated from RBC and WBC. The plasma 
is transferred in to a tube containing 0.1ml cacl2 (13). 
 
                  Christos Thanasas et al used a gps 3 system for PRP preparation. 27 
to 55 ml of blood was collected with 3-5ml of anticoagulant. They centrifuge the 
whole blood at 3200rpm for 15 minutes and finally give 3-6ml of PRP (14). 
 
                 T M Bielecki et al in an in vitro study prepared PRP using a gps 1 
system where 54 ml of whole blood was collected in a tube containing 6 ml of 
citrate solution. The whole blood was centrifuged for 12 minutes at 3200 rpm and 
finally gives 6 ml of PRP (38). 
 
                   Augustus D Mazzocca et al used 3 different types of PRP 
preparation methods. An arthrex ACP syringe is used in one method and gps 3 
platelet concentrating system in other method. Both the systems used only single 
spin. In the third type they used a double spin method with 1st centrifugation at 
1500 rpm and second centrifugation at 6300 rpm (23). 
              Samir Mehta in his article on platelet rich concentrate described about a 
non centrifugation method of PRP preparation using assay device. 60 ml of 
anticoagulated whole blood is mixed with priming solution and allowed to flow 
through a filter device. After back flushing using sterile solution PRP was 
obtained. The PRP so obtained are similar to concentration which was obtained 
by centrifugation method and the process is 40 percent faster than the 
centrifugation method (15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRP ACTIVATION: 
      Activation of PRP releases growth factors rapidly, with 90% released in 10 
minutes. Most growth factors have short half lives and effectiveness will be more 
if PRP are activated. PRP can be activated exogenously before injection by 
thrombin, cacl2 and endogenously by mechanical trauma. Once PRP is activated a 
fibrin network forms, solidify plasma and creates a fibrin clot or membrane. The 
fibrin network will be an unstable network if PRP is activated too strongly. A 
physiological manner of activation forms a more stable tetra molecular network 
which enhances enmeshment of cells and growth factors (18). 
                     Most PRP kits available commercially do not activate PRP. To avoid 
unintentional activation by injuring cells, large bore needles are used, to draw 
blood and reinjection. Similarly braking systems of centrifuge machines also have 
a role in unintentional activation. 
 Stefano Gumino et al used autologous thrombin for platelet activation (34). Juan 
Ramon Valenti Nin et al used 10% cacl2 for activation of platelets intra operatively 
(32). Kenneth S Lee et al described that  needle prick at the time of injection will 
induce bleeding which will provide the clotting factor thrombin need for 
activating platelets(19).   
ANIMAL STUDIES 
1 
Jason L Dragoo et al in a study on rabbit evaluated the inflammatory effect of 
leukocyte-rich PRP and leukocyte-poor PRP  after intratendinous injection (30). 17 
New Zealand White rabbits used for testing. Healthy patellar tendons were used. 
2 mL autologous whole blood in one patellar tendon, and the other with 2 mL 
sterile saline was injected in control animals. Seven tendons with whole blood 
and 7 tendons with saline were injected. In the study rabbits, one tendon with 2 
mL LR-PRP, the other with 2 mL LP-PRP was injected. Ten tendons with LR-PRP 
and 10 tendons with LP-PRP were injected. After injection Animals euthanized at 
5 or 14 days. Tendons were stained by hematoxylin and eosin and scored for 
WBCs, macrophages and lymphocytes, PMNs, vascularity and fibrosis. They 
concluded that leukocyte-rich PRP causes greater acute inflammatory response at 
5 days. There was no difference in the inflammatory response and cellularity at 14 
days regardless of type of injection (30). 
 
 
 
2 
Torricelli P et al published an article with the aim to evaluate the efficacy of  
administrating  a combination of autologous PRP and bone marrow 
mononucleated cells (BMMNCs) by conducting study in 13 competition horses 
affected by overuse  injuries (suspensory ligament desmopathy and superficial 
flexor tendinopathy)(25) . After USG localization, the autologous BMMNC and PRP 
injected directly into the lesion. BMMNC, platelet count and growth factors in PRP 
were measured. They found that a marked improvement in their degree of 
lameness and 84.6% return to competition. Among the factors, the platelet 
concentration predicted the healing time: significantly faster recovery (p 0.049) 
observed with cases of PRP > 750 *10(3)/μl platelets (25). 
3 
Kaux J F et al did a study to find whether PRP will accelerate the healing process 
of ' Achilles tendons after surgical induced lesion in rats (26). Surgically 5 mm 
defect was induced in Achilles tendon of 90 rats. Two groups of 45: (A) control (no 
treatment) and (B) PRP treatment were formed. Group B got PRP injection in situ 
after the surgery. Rats of both groups placed in cages without immobilization. 10 
traumatized Achilles tendons of each group were dissected after 5, 15 and 30 
days. Tendons were also submitted for a tensile test up to rupture. They found 
that the force necessary for inducing rupture during tensile test was more for 
tendons which had a PRP injection than the control group(26) 
4 
Jason W hammond et al done a study in rats to identify the use of autologous PRP 
in treatment of muscle strain injuries (27).  Tibialis anterior muscles of rats were 
injured by single or multiple lengthening contractions which causes a significant 
injury in vivo. Tibialis anterior was injected either with PRP, platelet poor plasma 
or without any treatment. They concluded that local delivery of platelet rich 
plasma decreases the recovery time for muscle injuries (27). 
 
5 
Hans T M et al done a placebo controlled trial to test the hypothesis that “a single 
intra-tendinous PRP treatment would enhance the quality of tendon repair” (28).  
6 horses, well-defined, standardized tendon lesions were surgically created in the 
Superficial Flexor tendons in both front limbs; one was treated with PRP and the 
other with saline after 1 week of surgery. Repair processes were monitored 
regularly by a novel method for computerized ultrasonographic tissue 
characterization (UTC) and by Doppler flowmetry.  After 24 weeks the tendons 
were taken for biomechanical,biochemical and histological evaluations. They 
found that PRP affects all phases of repair. Less inflammation (first 2 weeks post-
treatment), better early fibrillogenesis (starting from 1 till 7 weeks), advanced 
organization and remodeling (starting from 11 weeks) were noted. On Doppler 
neovascularization was increased during all phases in PRP group (28). 
6 
Arguelles D et al in a study to find the use of PRP on soft tissue injuries (29).he 
conducted the study in horses. 7 horses were selected for the study. They had 
injury to tendons and ligaments. They gave PRP thrice with 2 weeks gap. They 
followed up using USG. They assessed after 2 months of treatment. After 1 year of 
treatment they also checked the status. Before injection they checked the counts 
of cells in PRP. All the horses treated with PRP injection participated in 
competition following the recovery. They found the performance was good after 
the treatment with PRP (29).  
 
 
 
 
 
 
HUMAN STUDIES: 
    1                             Taco gosens et al done a study on patients who had chronic 
tennis elbow (31). They used 2 treatment methods. They used PRP and steroid 
injections for treatment. A total of 100 patients were included in that study. Out 
of 100 patients a computer allocated the patients in to 2 groups. First group had 
51 patients and second group had 49 patients. First group was treated with PRP 
and second group was treated with steroid injection. Before and after the 
injection they used VAS and DASH scoring system for the assessment of patients 
condition. The follow up period was 2 years from the time of injection. The results 
they got showed good improvement in patients treated with PRP than steroid 
group. They concluded that PRP had good effect in treating tennis elbow (31). 
 
  2 
                            Suzan de jonge et al done a study with the aim of finding the use 
of PRP in treating tendinopathy (32). They selected achilis tendinopathy for their 
study. The criteria they used was tendinopathy at 2-7 cm from insertion of 
tendon. They selected 44 patients for their study. Pre injection and post injection 
assessed with USG and they used one scoring system. The scoring system they 
used was VISA. They had a control group whom they given only saline injection. 
Both the group had tendinopathy and both group undergone severe exercises. 
After the study period they analyzed the results and found the patients in both 
group improved by the scoring system and by USG evidence. 59% of patients 
improved in both group and they cannot make any difference in the groups (32).  
3 
Allan mishra et al done a study to identify the effect on chronic severe elbow 
tendinitis using buffered platelet-rich plasma (33). 140 patients with epicondylar 
elbow pain were included in this study. All patients were given a physical therapy 
which was a standardized protocol and other non operative treatments. 20 
patients had pain persistently for a mean of 15 months in spite of these 
treatments. Surgery was considered for all patients. This cohort of patients who 
had failed conservative treatment was then given either a single platelet-rich 
plasma or bupivacaine injection. They found those 8 weeks after the injection, the 
platelet-rich plasma group noted 60% improvement in their VAP scores and 16% 
improved in control group. 60 percent (3 of 5) of the control subjects withdrew or 
sought various treatments after the 8-week, preventing further direct analysis. At 
6 months, the patients who got PRP treatment had 81% improvement in visual 
analog pain scores. At final follow-up of 12-38 months, the PRP patients had 93% 
reduction in pain compared with the before treatment (33). 
4 
 
Louay fallouh et al done a study aiming to find the treatment for acl injuries with 
PRP clots (21). They did study using the remnants of ACL those who underwent 
reconstruction. Autologous blood also collected from the patients. They created 
PRP clots and poor clots and they cultured the remnants of ligament in that. They 
also measured the growth factors in each and found that factors are high in PRP. 
They found collagen types grown in the culture. The culture medium which used 
PRP found high collagen 3 than the other mediums. Type 1 collagen was 
somewhat similar in the groups (21). 
5 
Stafano gumina et al done a study to evaluate “the clinical and magnetic 
resonance imaging (MRI) results of arthroscopic rotator cuff repair with and 
without the use of platelet-leukocyte membrane in patients with a large posterio 
superior rotator cuff tear, found that rotator cuff re tears were observed only in 
the group of patients in whom the membrane had not been used, and a thin but 
intact tendon was observed more frequently in this group” (34). They used 80 full 
thickness tear of rotator cuff patients and all the patients under gone arthroscopic 
repair and randomly used platelet rich membrane for the treatment. They used 
membrane in each anchor in whom undergone treatment with membrane. 
“Outcomes were the difference between the preoperative and postoperative 
Constant scores and the repair integrity assessed by MRI according to the Sugaya 
classification”. Another outcome they used was preoperative and postoperative 
Simple Shoulder Test scores. The results showed that “only significant differences 
between the two groups involved the patient age and the preoperative and 
postoperative Constant scores the differences in the Constant score were due to 
differences in the shoulder pain sub score” (34).  
6 
Ehab Mohamed selem ragab et al done a study “to find the effectiveness of PRP 
treatment for chronic plantar fasciitis” (1). The patient population they selected 
was 25 and they given injection for the 25 patients with PRP. The assessment was 
done using VAS and USG thickness of the fascia.  They followed up for 10 months. 
They found that “by the use of a visual analog pain scale, the average pre 
injection pain in patients of was 9.1 (range 8–10). Prior to injection, 72 % of 
patients had severe limitation of activities, and 28 % of patients had moderate 
limitation of activities. Average post-injection pain decreased to 1.6. Twenty-two 
patients (88 %) were completely satisfied, two patients (8 %) were satisfied with 
reservations, and one patient (4 %) was unsatisfied with using the visual analog 
scale” (1). 
7 
Ertugral aksahin et al did a study in plantar fasciitis patients by comparing the 
effect of platelet rich plasma and steroid injection (2). 60 patients selected by 
them had a conservative management for 3 months. 30 patients were given PRP 
injection and other 30 given steroid injection. They evaluated the Patients using 
the “modified criteria of the Roles and Maudsley scores and visual analog scale 
before injection and 3 weeks and 6 months following injection”. They found that 
the “ the mean pain score before the injection was 6.2 and 7.33 in steroid and 
platelet rich plasma group respectively which was reduced to 3.4 and 3.93 in each 
group after 6 months” . They concluded that “by the assessment of pain by visual 
score and roles and mausey score there were no significant difference in steroid 
and PRP group and both had significant decrease of pain at 6 months” (2). 
8 
Leon creaney et al in a study compared the “effect of PRP with autologous blood 
injection in elbow tendinopathy” (35). They selected 150 tennis elbow patients 
and treated 80 with PRP and the remaining 70 with whole blood. They assessed 
the patients using PRTEE score. At 6 months the authors observed a “66% success 
rate in the PRP group versus 72% in the ABI group, p=NS. There was a higher rate 
of conversion to surgery in the ABI group (20%) versus the PRP Group (10%)”.They 
concluded that the “patients who are resistant to first-line Physical therapies such 
as eccentric loading, ABI or PRP injections are useful second-line therapies to 
improve clinical outcomes” (35). 
9 
              Luigia scuddler et al done a study on bilateral epicondylitis comparing the 
effect between platelet rich lysate and wait and watch protocol. Outcome 
measures were by Visual analogue scale for pain on elbow Extension and resisted 
wrist extension. They found that Over six months’ follow-up, the patient 
experienced bilateral improvement in pain, but higher in the treated arm, with a 
drop in visual analogue scale for pain from 28 to 4 for right (control) arm (drop of 
24 points) and from 67 to 10.5 for left (treated) arm (drop of 56.5 points).  
10 
Lopez gavito E et al did a “Prospective, analytical study”. They selected patients 
with tennis elbow and plantar fasciitis and assessed usinf AOFAS scale along with 
VAS scale. The followed up for 2, 4, 8, and 12 months following PRP injection. 
They found that “a sample consisting of 10 patients (12 feet) that met the 
diagnostic and inclusion criteria was obtained. Mean age at the time of 
presentation was 43 years (range 23-56), with females being predominant (70%) 
and 50% laterality for the right and left feet”.  They also found that “the initial 
AOFAS score was 39 (range 28-68) and the VAS score was 9 (range 7-10). By week 
16 the AOFAS score had increased to 97 (range 88-99) and the VAS score was 2 
(range 1-4). All patients resumed independent gait”.  They concluded that PRP is a 
safe and alternative mode of treatment in tendinopathies and plantar fasciitis 
(36). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS: 
 
This is a prospective trial involving the patients in the department of 
orthopedics, PSGIMSR from April 2011 to April 2012. Prior consent was 
obtained from ethics committee for research in human beings before the 
study. 
            A total of 70 patients were included in this study. Out of 70 patients 25 
patients had tennis elbow and 45 patients had plantar fasciitis. All the patients 
were selected based on the inclusion and exclusion criteria described. All the 
patients underwent same method of treatment. All the patients were assessed 
based on the numerical pain scoring system which will be described.   
 
 
 
 
 
 
 
 
 
INCLUSION CRITERIA 
1. Patients with clinically diagnosed tennis elbow or plantar fasciitis 
2. Patients should have minimum three months duration of symptoms 
3. Patients should underwent  conservative treatment for a minimum period 
of three months 
4. Patients should have pain score greater than seven at the time of PRP 
injection. 
5. Patients should not had a local steroid injection in last 2 months 
6. Both sexes- males and female 
7. Age- 18 years and above 
 
 
 
 
 
 
 
 
 
 
EXCLUSION CRITERIA 
 
1. Less than 3 month duration of tennis elbow and plantar fasciitis  
2. Pain score less than seven 
3. Patients without any trial of conservative treatment 
4. Recent local steroid injection. 
5. Infection or ulcer at the injection site 
6. Rheumatoid arthritis 
7. Sero negative spondylo arthritis 
8. Pregnant ladies 
9. Patients younger than 18 years 
10. Suspicion of diagnosis 
 
 
 
 
 
 
 
 
 INFORMED CONSENT: 
 Informed consent was obtained from all the patients after explaining the 
disease condition and treatment with PRP injection in their local language. 
All the patients were informed about the study. All the patients agreed for 
the procedure and to participate in the study. All the patients and their 
nearest relative signed in the consent form. 
CLINICAL DIAGNOSIS: 
Diagnosis of tennis elbow was made when patient had pain in the lateral 
aspect of elbow joint. The pain would aggravate on wrist dorsiflexion. On 
examination the patient would have localized tenderness over lateral 
epicondyle. 
Diagnosis of plantar fasciitis was made when patient had heel pain. The 
pain was worse in the morning. Patient had localized tenderness over the 
insertion of plantar fascia over the calcaneum. 
 
 
 
 
 NUMERICAL PAIN SCORE 
Numerical pain score is a subjective assessment of pain, where the patient 
rates the intensity of the pain perceived. Score Zero refers to no pain. Score 
10 refers to the worst pain possible. 
On the basis of numerical pain score, intensity of pain was divided in to 
mild, moderate and severe. Score zero to three was taken as mild, four to 
six as moderate and seven to ten as severe pain.  
 
 
             
 
 
 
 
 
 PREPARATION OF PRP: 
Platelet rich plasma was prepared using double spin centrifugation method 
of Augustus D et al(25).20 ml of venous blood is drawn from cubital vein. 
The blood is immediately transferred into six 2.7ml vaccutainers prefilled 
with acid citrate dextrose. 2.7 ml Acid citrate dextrose containing 
vaccutainers are readily available in hospital. All the containers are filled till 
the markings on the vaccutainers. The vaccutainers are then placed in the 
slot available in the centrifugation machine in such a way that they are 
counter balanced. The initial centrifuge was done at 1500 rotations per 
minute for three minutes. This separates the blood into two layers. RBC rich 
at the bottom and plasma along with the platelets are at the top (figure 1). 
The top layer is then transferred to fresh vaccutainers using a long 18 G 
needle and syringe. The vaccutainers are now again centrifuged at 2500 
rotations per minute for three minutes. This separates the column of 
plasma to platelet rich at the bottom and platelet poor at the top.  Using a 
long 18 G the top half column which is platelet poor is discarded. The 
platelet rich plasma at the bottom is now collected from the vaccutainers 
and is now ready for use.  
 Figure 1 
Figure 2 
 
 
 
 
 
PLASMA 
RBC 
PLATLET POOR PLASMA 
PLATLET RICH PLASMA 
  After the preparation of PRP, the cell counts in the sample is assessed using the --
----- machine. The platelet count in the sample   ranged from 2.1 to 5.9 lakhs.  
 
TECHNIQUE OF INFILTRATION: 
Most tender point was palpated and marked using a skin (figure 3) marker 
and area was prepared for injection. Under aseptic precaution using a 21 
and 1 1/2 inch needle, 1ml PRP is injected initially over the maximum 
tender point and needle is partially withdrawn and multiple punctures are 
made in the surrounding tissue (peppering technique). The remaining 1 ml 
of platelet rich plasma was injected in surrounding tissue. 
 Injecting PRP in tennis elbow patient  
 
Injecting PRP in plantar fasciitis patients 
 
PLATELET ACTIVATION: 
According to Kenneth s lee et al needling of surrounding tissue will activate 
the platelets by the release of thrombin from the fresh bleeding. We used 
this technique for platelet activation (19). 
 
FOLLOW UP: 
Patients were followed up for 6 months. A telephonic follow up was done 
at second day after injection to find out any adverse reactions. Follow ups 
was done at 1,2,4,6 months. Patients were assessed subjectively using the 
numerical pain score.  
 
 
 
 
 
 
 
 
 
 
RESULTS AND ANALYSIS: 
Patients were analyzed for pain relief subjectively at 1, 2, 4 and 6 months. The 
results are given below. 
 
 
MEAN PAIN SCORE: 
Pain score was assessed at the time of injection. The mean pain score of all the 
patients was 8.614. The mean pain score at 1,2,4,6 months was 4.028, 2.57, 2.52 
and 2.62 respectively. When individually analyzed mean pain score for plantar 
fasciitis at 0, 1,2,4,6 months was 8.68, 3.68, 2.155, 2, 2.13 respectively.  similarly 
mean pain score for tennis elbow at 0,1,2,4,6 months was 8,08,4.36,3.56,3.48,3.6 
respectively. From the above data it can be inferred that patient get maximum 
relief of symptoms at two months and is sustained till at least 6 months (chart no 
1). 
 
 
                
 
 
PATIENTS MEAN PAIN 
SCORE AT 
TIME OF 
INJECTION 
MEAN PAIN 
SCORE AT 
1
ST
  MONTH 
MEAN PAIN 
SCORE AT 
2
ND
  
MONTH 
MEAN PAIN 
SCORE AT 
4
TH
 MONTH 
MEAN PAIN 
SCORE AT 
6
TH
 MONTH 
TOTAL (70) 8.614 4.028 2.57 2.52 2.62 
PLANTAR 
FASCIITIS 
(45) 
8.68 3.68 2.155 2.00 2.13 
TENNIS 
ELBOW (25) 
8.08 4.36 3.56 3.48 3.60 
               Chart no 1.                          Mean pain score  
 
                                    Graph no 1: mean pain score 
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PERCENTAGE REDUCTION OF PAIN: 
 Patients were analyzed for percentage reduction of pain. Percentage 
reduction of pain is obtained by calculating the percentage of the 
difference of pain score at every follow up from initial pain score at the 
time of injection.  Out of the 70 patients 15 patients had 100 percent pain 
relief at one month and 30 patients at two months. This was sustained till 
the end of study. One patient had recurrence at four months. However 77 
percentages of patients (54 out of the 70) had significant relief of pain 
(more than 50 percentage pain relief) at the end of two months, which was 
sustained till the end of study. 11 percentage (11 out of 70) patients did not 
benefit at all after the injection. 2 patients out of 70 had recurrence of pain 
in spite of early relief (chart no 2).  
 
 
 
 
 
 
 
 
  
 
 
 100% PAIN 
RELIEF 
50-99% PAIN 
RELIEF 
LESS THAN 
50% PAIN 
RELIEF 
0% PAIN 
RELIEF 
1
ST
  MONTH 
FOLLOW UP 
15(21.42%) 27(38.57%) 19(27.14%) 9(12.85%) 
2
ND
 MONTH 
FOLLOW UP 
30(42.86%) 24(34.286%) 8(11.43%) 8(11.43%) 
4
TH
 MONTH 
FOLLOW UP 
31(44.286%) 25(35.71%) 6(8.57%) 8(11.43%) 
6
TH
 MONTH 
FOLLOW UP 
30(42.86%) 24(34.286%) 8(11.43%) 8(11.43%) 
 
                    Chart no- 2        percentage reduction of pain in total patients 
                         Block diagram no 1: percentage reduction of pain in total patients
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Analyzing patients separately for plantar fasciitis and tennis elbow, patients 
with plantar fasciitis fared better (82 percent) compared to tennis elbow 
(68 percent). (Chart no 3 and 4)  
 
 100% PAIN 
RELIEF 
50-99% PAIN 
RELIEF 
LESS THAN 
50% PAIN 
RELIEF 
0% PAIN 
RELIEF 
1
ST
  MONTH 
FOLLOW UP 
10(22.22%) 19(42.22%) 12(26.67%) 4(8.89%) 
2
ND
 MONTH 
FOLLOW UP 
22(48.89%) 15(33.33%) 5(11.11%) 3(6.67%) 
4
TH
 MONTH 
FOLLOW UP 
22(48.89%) 17(37.78%) 3(6.67%) 3(6.67%) 
6
TH
 MONTH 
FOLLOW UP 
22(48.89%) 15(33.33%) 5(11.11%) 3(6.67%) 
 
               Chart no 3: percentage reduction of pain in plantar fasciitis patients 
 
  
 
 
 
 
                   Block diagram no 2: percentage reduction of pain in plantar fasciitis patients 
 
  
 
 
 100% PAIN 
RELIEF 
50-99% PAIN 
RELIEF 
LESS THAN 
50% PAIN 
RELIEF 
0% PAIN 
RELIEF 
1
ST
 MONTH 
FOLLOW UP 
5(20%) 8(32%) 7(28%) 5(20%) 
2
ND
 MONTH 
FOLLOW UP 
8(32%) 9(36%) 3(12%) 5(20%) 
4
TH
 MONTH 
FOLLOW UP 
9(36%) 8(32%) 3(12%) 5(20%) 
6
TH
 MONTH 
FOLLOW UP 
8(32%) 9(36%) 3(12%) 5(20%) 
 
      
                 Chart no 4: percentage reduction of pain in tennis elbow patients 
 
 
  
 
 
 
 
                                 Block diagram no 3: percentage reduction of pain in tennis elbow patients 
 
 
 
DURATION OF SYMPTOMS: 
Out of total 70 patients 59 patients had symptoms of less than one year duration. 
11 patients had pain for more than one year before coming here for treatment. 
All patients had conservative treatment for at least three months (chart no 5).  
 
 3-6 MONTHS 7-12 MONTHS MORE THAN 1 
YEAR 
TOTAL 
PATIENTS(70) 
35 24 11 
PLANTAR 
FASCIITIS(45) 
24 18 3 
TENNIS    
ELBOW(25) 
11 6 8 
                            Chart no 5: Duration of symptoms 
 
 
 
 
DURATION OF SYMPTOMS AND PAIN RELIEF: 
Analysis was done based on the duration of symptoms and ultimate pain relief. 16 
out of the 35 patients with pain of less than 6 months, 9 out of 24 patients with 
duration of symptoms between 6-12 months and 5 out of 11 with symptoms of 
greater than one year had complete relief of pain. 2 out of 35 patients with pain 
less than 6 months, 4 out of 24 patients with pain for 6-12 months, and 2 out of 
11 with pain greater than 1 year duration had no improvement of symptoms at six 
months (chart no-6). Duration of symptoms had no significant correlation with the 
clinical outcome after injection. 
 
 
 
 
 
 
 
 
  
 
 
 100% PAIN 
RELIEF 
50-99% PAIN 
RELIEF 
LESS THAN 
50% PAIN 
RELIEF 
0% PAIN 
RELIEF 
3-6 MONTHS 16(22.86%) 13(18.57%) 4(5.71%) 2(2.86%) 
7-12 MONTHS 9(12.86%) 9(12.86%) 2(2.86%) 4(5.71%) 
MORE THAN 1 
YEAR 
5(7.14%) 2(2.86%) 2(2.86%) 2(2.86%) 
Chart number 6:  PAIN REDUCTION RELATED TO DURATION OF SYMPTOMS IN TOTAL PATIENTS 
 
 
 
 
STATISTICAL ANALYSIS: 
SPS software system was used to do statistical analysis by comparing the results of 1,2,4,6 
months. P value for the test was taken as 0.05.  
Group Statistics  
 
 
Number of patients Mean percentage 
reduction of pain  Std. Deviation Std. Error Mean 
    
Plantar 
fasciitis 
Tennis 
elbow 
Plantar 
fasciitis 
Tennis 
elbow 
Plantar 
fasciitis 
Tennis 
elbow 
Plantar 
fasciitis 
Tennis 
elbow 
1 
month 45 25 57.6544 47.5000 33.18452 36.38205 4.94686 7.27641 
2 
month 45 25 75.6796 57.6108 31.88905 37.63747 4.75374 7.52749 
4 
month 45 25 77.4080 58.6108 30.10367 38.44225 4.48759 7.68845 
6 
month 45 25 75.8647 57.2776 32.22099 37.92296 4.80322 7.58459 
 
 
 
 
Independent Samples Test  
 
 
Equal variances assumed 
Levene's Test for Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) 
1 month .683 .411 1.185 68 .240 
2 month 1.483 .227 2.129 68 .037 
4 month 3.389 .070 2.264 68 .027 
6 month 1.762 .189 2.170 68 .034 
The mean pain score at 2
nd
, 4th and 6
th
 month found to significantly equal but pain 
score at 1 month was not significantly equal. 
 
Paired Samples Statistics  
 
 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 
1 month 54.0279 70 34.44765 4.11728 
2 month 69.2264 70 34.88885 4.17002 
Pair 2 
2 month 69.2264 70 34.88885 4.17002 
4 month 70.6947 70 34.26667 4.09565 
Pair 3 
4 month 70.6947 70 34.26667 4.09565 
6 month 69.2264 70 35.25239 4.21347 
Pair 4 
2 month 69.2264 70 34.88885 4.17002 
6 month 69.2264 70 35.25239 4.21347 
  
 
 
Paired Samples Correlations  
 
 
 N Correlation Sig. 
Pair 1 1 month & 2 month 70 .765 .000 
Pair 2 2 month & 4 month 70 .983 .000 
 
Paired Samples Test  
 
 
 
Paired Differences 
T df Sig. (2-tailed) 
Mean Std. Deviation 
Std. Error 
Mean 
95% Confidence Interval of 
the Difference 
 
 
 
Lower 
Upper 
 
 
 
Pair 
1 
1 month - 2 
month 
-
15.1986 23.75019 2.83869 -20.8616 -9.5355 
-
5.354 69 .000 
Pair 
2 
2 month - 4 
month -1.4683 6.39264 .76407 -2.9926 .0560 
-
1.922 69 .059 
Pair 
3 
4 month - 6 
month 1.4683 9.34823 1.11733 -.7607 3.6973 1.314 69 .193 
Pair 
4 
2 month - 6 
month .0000 13.77992 1.64702 -3.2857 3.2857 .000 69 1.000 
 
 
When comparing the significance of pain reduction it was found that there was 
significant pain reduction till two months and further the reduction was not significant. 
This indicates there was not much reduction of pain after 2
nd
 month. 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION: 
 
Platelet contains biologically active substance for blood clotting, such as 
coagulation factors, adhesive proteins and protease inhibitors. Platelets were also 
known to release growth factors like TGF –beta 1, CGF, VEGF, and PDGF. These 
growth factors are released once the platelets were activated.  These growth 
factors initiates the process of  tissue healing by cellular proliferation and 
differentiation, chemo taxis, tissue debris removal, angiogenesis, and extra 
cellular matrix formation (5). These properties of tissue healing by platelets are 
used in treating degenerative enthasopathies like plantar fasciitis and tennis 
elbow by direct local injection of autologous platelet rich concentrate. 
                       Various techniques have been described for the preparation of 
autologous platelet rich plasma. They differ in duration and speed of 
centrifugation. The containers used for platelet rich plasma preparation also differ 
to minimize the direct handling of blood. The volume of  platelet rich plasma 
usually comes about 10 percent of the whole blood used.   Alsousou et al used a 
gps system for preparation of PRP. The prp volume of about 5 ml was collected 
following 12 minutes of rotations at 3200 rpm (5). Augustus D et al used a double  
centrifugation method which separates blood first in to plasma and RBC. The 
plasma formed was separated again in to platelet rich plasma and platelet poor 
plasma by second centrifugation (23). In this study Augustus D et al method of 
double centrifugation was used. By repeated trial and error method we 
standardized the procedure of preparation of platelet rich plasma.   
 
                    Platelet rich plasma is also known as platelet rich concentrate, 
autologous platelet gel or platelet releasate (15).platelet rich plasma is defined as 
autologous blood with a concentration of platelets above the base line values. 
The platelet count in our samples ranged from two to six lakhs per cc. Hall m.p. et 
al described platelet rich plasma contains a two to eight fold increase in platelet 
concentration and 1-25 fold increase in growth factor concentration (14). 
According to Marx R E et al in an article “what is prp and what is not PRP?” 
described that at least 10 lakhs of platelet per ml in five ml of plasma, will be 
associated with enhancement of healing. Alsousou J et al in a review article 
described a concentration of five times the normal count as working definition of 
PRP (5).  
 Growth factor concentration can be assessed by ELISA. Concentration of growth 
factors also depends on the method of preparation of prp. Augustus et al found 
that growth factors like HGF, IGF-1, and PDGF will be high in single centrifugation 
than in double centrifugation (23). Since the assay of growth factors was not cost 
effective we did not do assay of growth factors. 
 
                        PRP can be divided in to low WBC PRP and high WBC PRP depending 
on WBC concentration. Augustus D et al found that WBC count is low in platelet 
poor plasma and high in platelet rich plasma (23).They found that there were no 
significant difference in WBC cell types in platelet poor plasma and platelet rich 
plasma (23). The concentration of WBC in prp was a subject of debate. Some 
authors recommended avoiding exposure of WBC to tissues so that inflammatory 
reaction may decrease. Bielecki T M et al support the WBC presence as it has 
antibacterial actions and increase in growth factor release (38). 
                  Platelets in PRP get activated once they get released from circulation. 
Different techniques have been used by various authors for platelet activation. 
Kenneth s lee et al described that needle prick at the time of injection will induce 
bleeding which will provide the clotting factor thrombin need for activating 
platelets. Addition of substances like bovine thrombin, calcium chloride and type 
1 collagen for activating platelets (18). In this study Kenneth s lee et al technique 
of needling was used for platelet activation (19). 
Most of the authors used similar technique of infiltration for PRP treatment.  
Keith s Hetchman et al, Joost .c. Peerbooms et al, Ertugrul Aksahin et al, Ehab 
Mohammed selem Ragab et al, used similar technique. They palpated the point of 
maximum tenderness and injected by single skin portal and five to six 
penetrations in surrounding tissues. This technique was known as peppering 
technique. In this study we used same technique for injecting platelet rich plasma 
in plantar fasciitis and Tennis elbow patients. 
                     This was a prospective trial by study design conducted on 70 patients 
which includes 45 patients with plantar fasciitis and 25 patients with tennis 
elbow. Both groups of patients were selected based on the inclusion criteria and 
exclusion criteria described. Patients having chronic inflammatory conditions like 
rheumatoid arthritis are excluded from the study.  Assessment of progression was 
done based on numerical pain scoring system. 
                      The following are some studies, investigated the efficacy of PRP on 
tennis elbow and plantar fasciitis. The studies on plantar Fasciitis were conducted 
by Joost c Peerbooms et al (22), Ehab Mohammed selem Ragab et al (1) , Ertugrul 
Aksahin et al (2) etc. Joost c peerbooms et al done a randomized multicenter trial 
with a study population of 120 patients above eighteen years. They compared the 
results with steroid injection by randomly selecting patients for PRP and steroid 
injections. The outcome was measured based on pain and functional scores. 
Ertugrul Aksahin et al did a similar study by comparing the effect of PRP and 
steroid injection on plantar fasciitis. The study population was 60 with 30 each 
patients got PRP and steroid injections.  Ehab Mohamed selem Ragab et al did a 
study on 25 plantar fasciitis patients by injecting PRP. The outcome was measured 
by comparing preinjection and post injection visual analog score and plantar 
fascia thickness by ultrasound (1). There was no control group in his study 
                     Following are some studies conducted on tennis elbow patients 1. 
Christos Thanases et al by comparing PRP to whole blood for tennis elbow (14). 2. 
Samuel A Taylor et al on 100 tennis elbow patients compared between PRP and 
steroid injection (11). 3. Keith s Hetchman et al on 31 elbows which was not 
responded for conservative treatment by single PRP injection (13). 
 
While comparing the results at 1,2,4,6 months follow up, it was found that 
patients got relief at one month. However the maximum relief of symptoms was 
at two months. The results obtained at two months sustained till the end of the 
study except in two patients. One patient with tennis elbow and one patient with 
plantar fasciitis had recurrence of symptoms at four months. While considering 
the results in plantar fasciitis and tennis elbow patients separately it was found 
that results of plantar fasciitis were better than tennis elbow. 82percent of 
plantar fasciitis patients and 68 percent of tennis elbow patients had more than 
50 percent of pain relief at six months. No patients had repeat injections. The 
above results were comparable with Ertugral Aksahin et al and Christos Thanases 
et al study (2, 14). The study of Christos Thanasas et al in tennis elbow the mean 
injection score was reduced from 6.1 to 2.35 at the end of 6 weeks, at 3 months 
1.9 and 6 months 1.7. In a study by Ertugral Aksahin et al on plantar fasciitis 
patients the mean pain score was reduced from 7.33 to 5.6 at 3 weeks and 3.9 at 
6 months.  
The difference between 1, 2, 4 and 6 months pain reduction were tested for 
significance by paired T – test using SPS system and found that there was no 
significant difference in pain reduction between 2 months and 4 months, 2 
months and 6 months, 4 months and 6 months scores. But there was significant 
difference in pain score in 1 and 2 months. By testing independent samples T-test 
using equal variances assumed found that 2 months, 4 months and 6 months pain 
reduction was significantly equal in all groups. 
Duration of symptoms suggests the chronic nature of disease. In this study only 
11 out of 70 patients had symptoms more than one year duration.  7 patients out 
of 11 had more than fifty percent pain relief compared to 18 patients out of 59 
with less than one year duration.  No studies are available to compare the 
chronicity of disease and outcome after PRP injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
 
1.  No control group was used and hence available for comparison in this 
study. 
  
2. Assessment was subjective based on patient’s perception of pain and no 
other objective assessment was done. 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Plantar fasciitis and tennis elbow are two diseases having similar pathology and 
both are considered as degenerative tendinopathies. Repeated micro trauma is 
the major etiology of these two diseases. Autologous platelet rich plasma 
injections are becoming more popular in the treatment of enthasopathies like 
plantar fasciitis and tennis elbow. The growth factors in platelet rich plasma cause 
tissue healing. We conducted a study by intralesional autologous platelet rich 
plasma injections in chronic plantar fasciitis and tennis elbow patients. This was a 
prospective study conducted on total 70 patients, out of which 45 patients had 
plantar fasciitis and 25 patients had tennis elbow. Patients were selected based 
on the inclusion and exclusion criteria described. All the patients had similar form 
of treatment given that is single intralesional autologous PRP injection by 
peppering technique. Platelet rich plasma was prepared by a double 
centrifugation method initially at 1500 rotations per minute for 3 minutes and 
later at 2500 rotations per minute for 3 minutes. 2ml of PRP was obtained from 
20ml of blood. This PRP was analyzed for cell count. The initial and 1,2,4,6 
month’s numerical pain score was recorded and analyzed. It was found that 77 
percent of patients had significant relief of pain at two months which continued 
till the end of study. Pain relief in plantar fasciitis and tennis elbow patients were 
analyzed separately and found 82 percent of plantar fasciitis patients and 68 
percent of tennis elbow patients had significant pain relief at two months and it 
continued till the end of study. Duration of symptoms to pain relief were analyzed 
and found no correlation. Finally it was concluded that intralesional autologous 
platelet rich plasma injection was safe and useful in the treatment of chronic 
plantar fasciitis and tennis elbow and plantar fasciitis benefit better than tennis 
elbow with maximum benefit observed at 2 months.   
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 Autologous PRP injection is a safe and useful modality of treatment in the 
treatment of chronic plantar fasciitis and tennis elbow.  
The response of patients with plantar fasciitis was significantly better than tennis 
elbow to platelet rich plasma injection. 
Maximum benefit after PRP injection was observed at 2 months and sustained for 
at least 6 months. 
More trails are required to optimize the technique for separating platelet rich 
plasma. 
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                                            CONSENT FORM 
Participant’s name: 
Address: 
 
 
Title of the study: 
EFFICACY OF AUTOLOGOUS PLATELET RICH PLASMA INJECTIONS IN 
PLANTAR FASCIITIS AND TENNIS ELBOW 
 
 The details of the study have been explained to me in my own language. I 
confirm that I have understood the above study and had the opportunity to ask 
questions. I understood that my participation in the study is voluntary and that I 
am free to withdraw at any time, without giving any reason, without the medical 
care that will normally be provided by the hospital. I agree not to restrict the use 
of any data or results that arise from this study provided such a use is only for 
scientific purpose(s). I fully consent to my participation in the above study. 
 
Signature of participant:                                                            date: 
 
Signature of witness 1:                                                               date: 
 
Signature of witness 2:                                                               date: 
 For any study related queries, you are free to contact: 
 
Name of investigator:      Dr. Parvees.ch 
                                              Junior resident 
                                              Department of orthopedics 
                                              Psgimsr 
                                              Coimbatore-641004 
                                              Phone: 9597130313 
 
 
Guide:                                 Dr. B K Dinakar Rai  
                                              Professor and head 
                                              Department of orthopedics 
                                              Psgimsr 
                                              Coimbatore-641004 
                                              Phone: 9894140052 
 
Place:                                                              signature of investigator 
Date:                                                                
 PSG INSTITUTE OF MEDICAL SCIENCE AND RESEARCH-COIMBATORE 
 
EFFECACY OF AUTOLOGOUS PLATELET RICH PLASMA INJECTIONS IN 
PLANTAR FASCIITIS AND TENNIS ELBOW 
Investigator:                                                                       Dr. Parvees.ch 
Guide:                                                                                  Dr. B K Dinakar Rai    
                                                   
 
PATIENT DETAILS: 
Name: 
Age: 
Sex: 
Hospital number: 
Disease: 
Duration of symptoms: 
Pain score: 
Date of injection: 
Follow ups: 
 1
st
  month 2
nd
 month 4
th
 month 6
th
 month 
    
 MASTER CHART 
SL 
NO
: 
NAME AG
E 
SE
X 
DISEASE DURATIO
N OF 
PAIN 
PAIN 
SCORE 
AT TIME 
OF 
INJECTIO
N 
PAIN 
SCORE 
AT 1
ST
 
MONT
H 
PAIN 
SCORE 
AT 2
ND
  
MONT
H 
PAIN 
SCORE 
AT 4
TH
  
MONT
H 
PAIN 
SCORE  
AT 6
TH
  
MONT
H 
1 VIJAYA 
LAKSHMI 
42 F PLANTA
R 
FASCIITI
S 
7 
MONTHS 
9 0 0 0 0 
2 PALANISAMY 41 M TENNIS 
ELBOW 
6 
MONTHS 
8 4 3 3 3 
3 SUBRAMANIA
M 
45 M PLANAT
R 
FASCIITI
S 
4 
MONTHS 
9 8 8 8 8 
4 SUSEELA DEVI 54 F PLANAT
R 
FASCIITI
S 
5 
MONTHS 
9 0 0 0 0 
5 SELVAN 33 M PLANTA
R 
FASCIITI
S 
6 
MONTHS 
8 2 0 0 0 
6 SAVITHRI 43 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
9 4 3 3 3 
7 JOTHI 35 F PLANAT
TR 
FASCIITI
S 
1 YEAR 9 6 4 4 4 
8 VALLIAMMAL 50 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
9 0 0 0 0 
9 BHARATHI 39 F PLANTA
R 
FASCIITI
S 
5 
MONTHS 
8 8 8 8 8 
10 RAMANI 33 F PLANTA
R 
1 YEAR 9 6 0 0 0 
FASCIITI
S 
11 MARIYA 
ANTHUVAN 
43 M TENNIS 
ELBOW 
8 
MONTHS 
8 8 8 8 8 
12 SUMATHI 34 F TENNIS 
ELBOW 
1 ½ YEAR 8 6 2 0 0 
13 GANESAN 68 M TENNIS 
ELBOW 
6 
MONTHS 
9 0 0 0 0 
14 GOKILA 50 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
8 6 4 4 6 
15 VIJAYALAKSHM
I.R 
50 F PLANTA
R 
FASCIITI
S 
1 YEAR 9 0 0 0 0 
16 SENBAGAVALLI 30 F PLANTA
R 
FASCIITI
S 
1 YEAR 9 2 0 2 8 
17 SEMBAGAM 42 F TENNIS 
ELBOW 
1 YEAR 8 8 8 8 8 
18 UMADEVI 37 F TENNIS 
ELBOW 
3 
MONTHS 
9 2 0 0 0 
19 MAHESWARI 38 F TENNIS 
ELBOW 
1 YEAR 8 8 8 8 8 
20 PANKAJAM 33 F TENNIS 
ELBOW 
1 ½ YEAR 8 2 0 0 0 
21 PADMAVATHI 54 F PLANTA
R 
FASCIITI
S 
8 
MONTHS 
9 1 0 0 0 
22 RASATHI 47 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
8 0 0 0 0 
23 KALIYAPPAN 59 M PLANTA
R 
FASCIITI
S 
3 
MONTHS 
9 0 0 0 0 
24 MANJULA 25 F PLANTA
R 
FASCIITI
S 
6 
MONTHS 
9 2 0 0 0 
25 VENKATA 
PRIYA 
35 M TENNIS 
ELBOW 
5 
MONTHS 
8 0 0 0 0 
26 ANNIEMMA 50 F TENNIS 2 YEARS 9 7 5 5 6 
ELBOW 
27 DHANABAGYA
M 
46 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
8 6 4 4 4 
28 SENTHIL 
KUMAR 
33 M PLANTA
R 
FASCIITI
S 
3 
MONTHS 
9 0 8 6 6 
29 SAVITHRI.M 43 F PLANTA
R 
FASCIITI
S 
1 ½ 
YEARS 
8 3 0 0 0 
30 RAVI 45 M TENNIS 
ELBOW 
1 YEAR 8 6 3 3 3 
31 THIRUNAVA 
KARASU 
56 M TENNIS 
ELBOW 
8 
MONTHS 
8 6 4 4 4 
32 GOVINDAMAL 51 F PLANTA
R 
FASCIITI
S 
6 
MONTHS 
9 9 0 0 0 
33 LAKSHMI 40 F PLANTA
R 
FASCIITI
S 
5 
MONTHS 
9 8 6 5 5 
34 RAJALAKSHMI 41 F TENNIS 
ELBOW 
4 
MONTHS 
9 3 2 2 2 
35 THANGAVEL 50 M TENNIS 
ELBOW 
6 
MONTHS 
9 0 0 0 0 
36 PARASURAMA
N 
46 M PLANTA
R 
FASCIITI
S 
3 
MONTHS 
9 0 0 0 0 
37 DARANIDHARA
N 
26 M PLANTA
R 
FASCIITI
S 
8 
MONTHS 
9 8 6 4 2 
38 MYLSAMY 37 M TENNIS 
ELBOW 
6 
MONTHS 
9 0 0 0 2 
39 SHANTHI 40 F TENNIS 
ELBOW 
3 
MONTHS 
9 6 6 6 6 
40 DEVAKI 42 F PLANTA
R 
FASCIITI
S 
4 
MONTHS 
9 2 1 0 0 
41 NARAYANI 61 F PLANTA
R 
6 
MONTHS 
9 0 0 0 0 
FASCIITI
S 
42 GANESHA 
MOORTHY 
63 M PLANTA
R 
FASCIITI
S 
8 
MONTHS 
9 0 0 0 0 
43 PRAMEELA 46 F PLANTA
R 
FASCIITI
S 
1 YEAR 9 9 9 9 9 
44 POONGODI 42 F TENNIS 
ELBOW 
1 ½ 
YEARS 
9 9 9 9 9 
45 VENKATA 
SAMY 
53 M PLANTA
R 
FASCIITI
S 
1 ½ 
YEARS 
9 2 0 0 0 
46 SARASWATHI 39 F TENNIS 
ELBOW 
8 
MONTHS 
8 6 4 4 4 
47 RANI 41 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
9 9 9 9 9 
48 SINDHU 36 F TENNIS 
ELBOW 
6 
MONTHS 
9 0 0 0 0 
49 KAVITHA 39 F PLANTA
R 
FASCIITI
S 
8 
MONTHS 
8 4 1 1 1 
50 RUKMANI 48 F TENNIS 
ELBOW 
1 ½ 
YEARS 
9 9 9 9 9 
51 USHA DEVI 52 F PLANTA
R 
FASCIITI
S 
6 
MONTHS 
9 7 3 2 2 
52 PADMAVATHI 58 F TENNIS 
ELBOW 
1 ½ 
YEARS 
9 7 7 7 7 
53 PIUS 
SAVARIMUTHU 
43 M PLANTA
R 
FASCIITI
S 
8 
MONTHS 
9 5 2 0 0 
54 MARIAMMAL 67 F PLANTA
R 
FASCIITI
S 
5 
MONTHS 
8 3 0 0 0 
55 MUTHUSAMY 59 M TENNIS 
ELBOW 
6 
MONTHS 
8 4 4 4 4 
56 LATHA 45 F PLANTA 3 9 4 0 0 0 
R 
FASCIITI
S 
MONTHS 
57 JAYALAKSHMI 61 F PLANTA
R 
FASCIITI
S 
8 
MONTHS 
8 3 3 3 3 
58 BHAMA 38 F PLANTA
R 
FASCIITI
S 
9 
MONTHS 
8 4 0 0 5 
59 SAROJINI 62 F PLANTA
R 
FASCIITI
S 
6 
MONTHS 
9 3 3 3 3 
60 PARVATHY 43 F PLANTA
R 
FASCIITI
S 
9 
MONTHS 
8 2 0 0 0 
61 GOMADHI 46 F PLANTA
R 
FASCIITI
S 
3 
MONTHS 
8 3 2 2 2 
62 SOUNDARAJ 39 M TENNIS 
ELBOW 
6 
MONTHS 
8 4 4 4 4 
63 KALAMANI 38 F PLANTA
R 
FASCIITI
S 
5 
MONTHS 
9 7 3 3 3 
64 MANOHARI 47 F PLANTA
R 
FASCIITI
S 
8 
MONTHS 
8 2 2 2 2 
65 PANKAJAM 53 F TENNIS 
ELBOW 
1 ½ 
YEARS 
9 2 0 0 0 
66 VIJAYALAKSHM
I. P 
58 F PLANTA
R 
FASCIITI
S 
1 YEAR 8 4 0 0 0 
67 KUTTIYAMMAL 64 F TENNIS 
ELBOW 
2 YEARS 8 3 3 3 3 
68 VIJAYA.P 50 F PLANTA
R 
FASCIITI
S 
8 
MONTHS 
9 4 3 3 3 
69 VARUNA 45 F PLANTA
R 
9 
MONTHS 
9 7 3 2 2 
FASCIITI
S 
70 SUSHA 52 F PLANTA
R 
FASCIITI
s 
3 
MONTHS 
9 3 3 3 3 
 
 
 
